Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.
Lancet Oncol
; 23(7): e318, 2022 07.
Article
in En
| MEDLINE
| ID: mdl-35772460
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
Limits:
Humans
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication: